Ovarian Cancer – Unmet Need – Unmet Need – Advanced Platinum-Sensitive Ovarian Cancer (US/EU)

The treatment landscape of advanced platinum-sensitive ovarian cancer has been revolutionized by poly ADP ribose polymerase (PARP) inhibitors (AstraZeneca’s and Merck & Co.’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca). With the approval of Lynparza and Zejula in the first-line maintenance setting, PARP inhibitors have become the new standard of care; however, these drugs provide the greatest benefit to patients with BRCA mutations or deficiencies in homologous recombination and have shown limited efficacy in patients without these genetic alterations. Availability of treatment options after disease progression is limited; the FDA’s enhanced scrutiny of PARP inhibitors led to withdrawals and label restrictions, creating further void. In addition, the optimal sequencing of therapies is not clear. A pressing unmet need remains for patients with advanced platinum-sensitive ovarian cancer.

QUESTIONS ANSWERED

• What are the key factors and goals driving medical oncologists’ prescribing decisions for advanced platinum-sensitive ovarian cancer?
• How do current therapies, such as Zejula and Lynparza, perform on key clinical attributes in this setting? Are medical oncologists satisfied with the available treatments?
• What are the most urgent unmet needs in advanced platinum-sensitive ovarian cancer? What are the most attractive opportunities for the development of novel therapies for this disease?
• What trade-offs are acceptable for U.S. and European physicians across key clinical attributes and price for a new drug for advanced platinum-sensitive ovarian cancer?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 31 European medical oncologists fielded in February 2023.

Key companies: AstraZeneca, GSK, Clovis Oncology

Key drugs: Lynparza, Zejula, Rubraca, bevacizumab